Program
risankizumab
Also written as “Risankizumab”, “risankizumab IV” and “risankizumab SC”.
Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.
Drug pageRisankizumab: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 6515 open or running | phase 4since May 28, 2021 | Apr 10, 2012 | Jan 2027phase 1 · NCT07466550 |
| Johnson & Johnson | 21 open or running | phase 3since Mar 23, 2026 | Oct 11, 2021 | Nov 15, 2028phase 3 · NCT07499232 |
| Boehringer Ingelheimits history only | 10 open or running | phase 2since Feb 3, 2014 | Feb 3, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named risankizumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BI 655066
- Oct 11, 2021First study: phase 1 study in Arthritis, PsoriaticFirst studyNCT05083078 · 11 enrolled · Austria
- Mar 23, 2026Phase 3 study in Crohn DiseasePhase 3 reachedNCT07499232 · 530 planned · United States, Austria, Belgium and more
Ahead
- Nov 15, 2028Primary completion: phase 3 study in Crohn DiseaseNCT07499232
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
| mirikizumabrule | Eli Lilly | phase 4 | 36 |
Studies
All 2 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07499232Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Nov 15, 2028 | 530 |
| NCT05083078Arthritis, Psoriatic · Austria | 1 | Terminated | Jul 1, 2022 | 11 |
How it is read
Names in the registry
- “Risankizumab”, 53 entries
- “risankizumab”, 17 entries
- “risankizumab IV”, 4 entries
- “risankizumab SC”, 4 entries
- “BI 655066”, 3 entries
Conditions, from the studies’ own filings
- Psoriasis, 25 studies
- Crohn Disease, 11 studies
- Arthritis, Psoriatic, 6 studies
- Colitis, Ulcerative, 5 studies
- Arthritis, Juvenile, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.